Globe & Mail Article
Globe/Dow say president and analyst support each other's expectations
Helix Biopharma Corp HBP
Shares issued 10,425,915 Nov 19 close $1.35
Thu 21 Nov 96 In the News
The Globe and Mail carries a Dow Jones dispatch in its Thursday edition
that reports that Helix Biopharma expects to report a $3.3 million loss for
the year ending July 31 1997, because of plans to spend $3.5 million on
pharmaceutical development in that period, according to president Terrance
Owen. Reporter Mary Weil says, however, that Mr Owen agrees with Griffith
McBurney analyst Bin Huang that the company will come close to reporting
break-even results in fiscal 1998. He sees "good profits" for 1999 and
2000, and he is comfortable with her estimates of $3.6 million in net
income for fiscal 1999 and $4.9 million for fiscal 2000. Helix, a
development stage biotechnology company, can be reasonably certain about
financial forecasts because it also runs an established laboratory products
and services division, according to Mr Owen. That division brought in $8
million in revenue in fiscal 1996, and along with a little help from the
company's generic pharmaceuticals division, is expected to bring in about
$12 million in revenue this fiscal year, according to Ms Huang.
(c) |
